GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (MEX:BLUE) » Definitions » EV-to-FCF

bluebird bio (MEX:BLUE) EV-to-FCF : -1.63 (As of Jan. 19, 2025)


View and export this data going back to 2019. Start your Free Trial

What is bluebird bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, bluebird bio's Enterprise Value is MXN7,897.9 Mil. bluebird bio's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-4,853.8 Mil. Therefore, bluebird bio's EV-to-FCF for today is -1.63.

The historical rank and industry rank for bluebird bio's EV-to-FCF or its related term are showing as below:

MEX:BLUE' s EV-to-FCF Range Over the Past 10 Years
Min: -47.43   Med: -3.05   Max: -0.03
Current: -1.4

During the past 13 years, the highest EV-to-FCF of bluebird bio was -0.03. The lowest was -47.43. And the median was -3.05.

MEX:BLUE's EV-to-FCF is ranked worse than
100% of 395 companies
in the Biotechnology industry
Industry Median: 7.5 vs MEX:BLUE: -1.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-01-19), bluebird bio's stock price is MXN186.00. bluebird bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-635.769. Therefore, bluebird bio's PE Ratio (TTM) for today is At Loss.


bluebird bio EV-to-FCF Historical Data

The historical data trend for bluebird bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio EV-to-FCF Chart

bluebird bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.48 -2.50 -0.76 -2.31 -1.53

bluebird bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.17 -1.53 -1.81 -1.72 -1.47

Competitive Comparison of bluebird bio's EV-to-FCF

For the Biotechnology subindustry, bluebird bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bluebird bio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where bluebird bio's EV-to-FCF falls into.



bluebird bio EV-to-FCF Calculation

bluebird bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7897.862/-4853.772
=-1.63

bluebird bio's current Enterprise Value is MXN7,897.9 Mil.
bluebird bio's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,853.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


bluebird bio  (MEX:BLUE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

bluebird bio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=186.00/-635.769
=At Loss

bluebird bio's share price for today is MXN186.00.
bluebird bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-635.769.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


bluebird bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of bluebird bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


bluebird bio Business Description

Traded in Other Exchanges
Address
455 Grand Union Boulevard, Somerville, MA, USA, 02145
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.